Equities Analysts Offer Predictions for Monte Rosa Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Research analysts at Wedbush upped their Q2 2024 earnings per share estimates for Monte Rosa Therapeutics in a note issued to investors on Tuesday, May 21st. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.37) per share for the quarter, up […]

Related Keywords

, Monte Rosa Therapeutics Inc , Acadian Asset Management , Corton Capital Inc , Vanguard Group Inc , Nasdaq , Entrypoint Capital , Exchange Traded Concepts , Monte Rosa Therapeutics , Free Report , Monte Rosa Therapeutic , Rosa Therapeutics , Get Free Report , Point Capital , Traded Concepts , Asset Management , Vanguard Group , Monte Rosa Therapeutics Daily ,